Suven Life Sciences Ltd

Q1 FY22Healthcare Services

Suven Life Sciences Q1 FY22 earnings call: Revenue & Margins

Q1 FY22 investor presentation: what the company reported on revenue, margins and projects.

Price₹335

Market cap₹9.7K Cr

Updated25 Sept 2026

Read3 min read

Based on Suven Life Sciences Ltd's Q1 FY22 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. The provided pages of the Suven Life Sciences Limited presentation do not contain any information or figures related to EBITDA, operating margin, profit (PAT), year-on-year changes, or explicit margin outlook for any quarter.

From Suven Life Sciences Ltd's Q1 FY22 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. There is also no mention of year-on-year changes in such financial metrics. Additionally, the presentation does not state any explicit outlook for revenue or sales volumes. The content primarily focuses on the company's CNS drug discovery and development pipeline, clinical trial statuses, and strategic direction rather than financial or sales performance data.

Profitability & Margins

The provided pages of the Suven Life Sciences Limited presentation do not contain any information or figures related to EBITDA, operating margin, profit (PAT), year-on-year changes, or explicit margin outlook for any quarter. The content focuses mainly on pipeline updates, CNS therapy development stages, company overview, and contact information. No financial metrics or related outlooks are reported in the shared document pages.

See what Suven Life Sciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The provided presentation does not mention any specifics about capex, capacity expansion, new plants, or projects related to such infrastructure. It focuses primarily on Suven Life Sciences' drug discovery and development pipelines in CNS therapies, clinical study statuses, and corporate overview without detailing capital expenditures or facility expansions.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹919 Cr

Rev 1Mar 1

2Chandan Healthca₹590 Cr

Rev 1Mar 3

3₹66.2K Cr

Rev 2Mar 1

4₹1.8K Cr

Rev 2Mar 2

5₹649 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The presentation does not mention any fundraising through debt or equity, nor does it mention any changes in borrowings or net debt. - No references to debt or equity fundraising activities. - No details on borrowings, loans, or changes in net debt.

2 more points management made on fundraising & capital structure

See what Suven Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not report or mention any specifics about order book, order inflow, or pending orders. The document primarily focuses on: - Suven Life Sciences’ CNS drug discovery and development pipeline. - Progress and status of various clinical candidates. - Company’s evolution, vision, and therapeutic focus.

2 more points management made on order book & pipeline

Suven Life Sciences Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹2 Cr, net loss ₹46 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Suven Life Sciences Ltd's management said in earlier quarters

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Suven Life Sciences Ltd Q1 FY22 results?

What is Suven Life Sciences Ltd share price analysis?

Suven Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹9,651 Cr. Investors should review the full earnings analysis for detailed insights.

Is Suven Life Sciences Ltd planning capital expenditure?

The provided presentation does not mention any specifics about capex, capacity expansion, new plants, or projects related to such infrastructure.

Keep Suven Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.